Dr. Elran Haber to participate in the Industry
Leaders opening panel at this premier
Microbiome conference
REHOVOT, Israel, June 15,
2022 /PRNewswire/ -- Biomica Ltd., an emerging
biopharmaceutical company developing innovative microbiome-based
therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN)
(TASE: EVGN), today announced it will be presenting as part of a
panel at the opening session of the 7th Microbiome
Movement Drug Development Summit taking place between June 21-24, 2022 in Boston, MA.
The event is known in the field as the most comprehensive forum
for microbiome drug developers and an opportunity for the industry
to take a collaborative approach, discuss next-generation
microbiome-based therapeutics and establish new partnerships.
In attendance will be Dr. Elran Haber, CEO of Biomica. Dr. Haber
will be part of the plenary opening industry leaders panel on
June 22, 2022.
Dr. Haber will be available for one-on-one meetings at the
conference, and those interested should be in touch with the
investor or public relations team.
About Biomica
Biomica is an emerging biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing a dedicated
Computational Predictive Biology platform (CPB), licensed from
Evogene. Biomica aims to identify and characterize disease-related
microbiome entities and to develop novel therapeutics based on
these understandings. The company is focused on the development of
therapies for antibiotic resistant bacteria, immuno-oncology, and
microbiome-related gastrointestinal (GI) disorders. Biomica is a
subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN). For more
information, please visit www.biomicamed.com.
Logo -
https://mma.prnewswire.com/media/1015458/Biomica_Logo.jpg
Contacts
Lital Mamon
Head of Marketing and PR
IR@evogene.com
+972-8-931-2097
Kenny Green
US Investor Relations
IR@evogene.com
+1-212-378-8040
View original
content:https://www.prnewswire.com/news-releases/biomica-to-present-at-the-7th-microbiome-movement-drug-development-summit-301568563.html
SOURCE Biomica Ltd.